Waters™

Utility of the ACQUITY UPLC I-Class System and Ion Mobility in a Routine Workflow to Understand the Challenge of Analyzing Fluoroquinolone Antibiotic Residues

Michael McCullagh, Ramesh Rao, Sara Stead

Waters Corporation



Abstract

This application note explores the use of routine screening with UPLC and ion mobility to identify multiple protonation sites and different fragmentation patterns within the fluoroquinolone class of antibiotics.

Benefits

- Unique protomer collision cross section (CCS) values can be determined and used as an additional identification parameter in a routine screening workflow.
- · Individual protomer spectra are generated along with proposed fragmentation pathways.
- The impact of matrix upon protomer ratios can be observed routinely using new ion mobility processing functionality within the UNIFI Scientific Information System.
- The ACQUITY UPLC I-Class System can be used in conjunction with ion mobility as a development tool to generate more robust analytical methods.
- · Ability to perform retrospective UPLC and ion mobility data review.

Introduction

Across many application areas, the applicability of ion mobility to small molecule analysis continues to increase, along with the understanding of how this technology can help address current analytical challenges. The reason, challenge, and methods of achieving successful fluoroquinolones analysis were briefly discussed in a previous application note, where we described the use of the ACQUITY UPLC I-Class System combined with ion mobility mass spectrometry to show how fluoroquinolone class of compounds can form protomers.¹⁻⁵ Identification and characterization of the protomers of fluoroquinolones can now be routinely screened for using Waters UNIFI Scientific Information System. The software within UNIFI allows for the routine characterization of fragmentation pathways of the respective protomers to be visualized. In addition, it is possible to see the direct impact of the matrix upon protomer formation, and hence obtain a greater INSIGHT of the challenges of using MRM to perform residue analysis of fluoroquinolones.

Fluoroquinolones are a family of synthetic broad-spectrum antimicrobial agents that have been administered to livestock for different purposes, including the prevention and control of infections and for growth promotion. Due to concerns regarding the spread of resistant microorganisms in the human population, the

U.S. Food and Drug Administration (U.S. FDA) introduced a ban on the use of enrofloxacin and ciprofloxacin in livestock production in September, 2005.⁷⁻⁹ The use of antibiotic growth promoting agents (AGPs) in animal husbandry has been forbidden in the European Union (EU) since 2006.¹⁰

This application note explores the use of routine screening with UPLC and ion mobility to identify multiple protonation sites and different fragmentation patterns within the fluoroquinolone class of antibiotics. It can be used as an important method development tool to support the unequivocal identification of fluoroquinolone antibiotics in crude tissue extracts. UPLC and ion mobility have been utilized to analyze crude extracts of porcine muscle tissue to determine the presence of antibiotic residues including the fluoroquinolone class.

The enhanced peak capacity provided by the combination of UPLC and ion mobility separation offers some unique advantages for profiling complex matrices. It uses a combination of high resolution mass spectrometry and high efficiency ion mobility-based measurements and separations. Ion mobility spectrometry (IMS) is a rapid, orthogonal, gas phase separation technique that allows another dimension of separation to be obtained within an LC timeframe. Compounds can be differentiated based on size, shape, and charge. In addition, both precursor ion and fragment ion information can be acquired in a single acquisition for all components.

A collision cross section (CCS) value is a robust and precise physicochemical property of an ion. CCS is an important distinguishing characteristic of an ion which is related to its chemical structure and threedimensional conformation, where the shadow of a rotating three-dimensional ion, shown in Figure 1, represents the average collision cross section. Using CCS measurements can increase targeted screening specificity. CCS measurements generated have been entered into a scientific library within UNIFI. This allows the expected and determined CCS values to be utilized in order to screen and confirm fluoroquinolone protomer formation. Here we present CCS values (derived from ion mobility drift times) as a new identification parameter, which can distinguish protomers.




Figure 1. Illustration of rotating three-dimensional conformation of an ion and average collision cross section (shadow).

Experimental

Analytes:

Standards fluoroquinolones

Extracts:

Porcine tissue

UPLC conditions

UPLC system:	ACQUITY UPLC I-Class
Column:	ACQUITY UPLC BEH C ₁₈ 1.7 μ m, 100 mm x 2.1 mm
Column temp.:	40 °C
Flow rate:	0.6 mL/min
Mobile phase A:	Water (0.1% formic acid)
Mobile phase B:	Acetonitrile (0.1% formic acid)
Injection volume:	10 µL

Gradient:

Time (min)	%A	%В
Initial	0.0	5.0
1.00	95.0	5.0
8.00	5.0	95.0
9.00	95.0	5.0

MS conditions

MS system: SYNAPT G2-S

Ionization mode:	ESI+
Capillary voltage:	2.0 kV
Cone voltage:	25 V
Desolvation temp.:	550 °C
Reference mass:	Leucine enkephalin [M+H] ⁺ = 556.2766
Acquisition range:	50 to 1200 Da
Acquisition rate:	4 spectra/sec
Collision energy:	15 to 45 eV
IMS T-Wave velocity:	900 m/s
IMS T-Wave pulse height:	40 V
IMS duty cycle:	10.8 ms
Drift gas:	N ₂

Extract preparation

Extracts of porcine muscle tissue were kindly provided by RnAssays BV for the purposes of this study. Briefly, known blank porcine muscle was fortified with 25 different antimicrobial compounds (from fluoroquinolone, tetracycline, and macrolide classes) at levels the relevant to the EU MRL concentrations prior to extraction. Tissue samples were mechanically homogenized in the presence of an aqueous/organic extraction solvent followed by a centrifugation step. An aliquot of the supernatant was removed and placed in an autosampler vial for subsequent LC-MS analysis.

Results and Discussion

For the assay performed, MassLynx MS data were acquired and processed with the UNIFI Scientific Information System, allowing ion mobility data to be processed in a conventional workflow for non-targeted accurate mass screening applications.

UPLC ion mobility MS has been explored as an important method development tool to support the unequivocal identification of fluoroquinolone antibiotics in crude tissue extracts. With UNIFI, it has been possible to routinely identify and characterize protomers of nine fluoroquinolones standards in a routine screening workflow.¹⁰ From the solvent standards analyzed, estimated CCS values of protomers formed for each fluoroquinolone were determined. The CCS values obtained have been incorporated into the UNIFI Scientific Library, which enabled the targeting of protomers.

The antibiotic ciprofloxacin was determined to elute at retention time 2.19 min using the generic gradient conditions employed. Figure 2 shows the base peak ion chromatogram with the UNIFI Component Plot Summary for nine of the identified fluoroquinolone antibiotics, which eluted in the region highlighted in the base peak intensity chromatogram. From review of the data using the Component Drift Plot Summary, 18 fluoroquinolone species were identified. Each fluoroquinolone is comprised of two protomers, i.e. protonation at two different sites on the molecule that have been mobility separated, as shown in Figure 3. Each retention time shows two dots on the Component Summary Drift Plot, which indicate two forms of each fluoroquinolone. The two protomers of ciprofloxacin have been highlighted. The CCS values determined are presented in the Component Summary table of Figure 4. The functionality illustrated is unique to the UNIFI Scientific Information System.




Figure 2. Base peak ion chromatogram for a mixture of 25 solvent standard antibiotic compounds, including nine fluoroquinolones. Also the Component Plot Summary is shown for 18 of the identified fluoroquinolone components between 2 and 2.6 minutes.




Figure 3. UNIFI Component Summary drift plot for nine pairs of fluoroquinolone protomers.

Injections View Accurate Mass Screening IMS REP. Item Name Type		🗄 👻 🚮 My Work		S Welcome to UN	IFI	🗿 Explorer	SYANPT G2 IMS FQS N	OF X	Search folders	۵ ام
etclons and Componishts ▼ Image: Line SynaptG2, 2012/20 [1] Component Summary View *Accurate Mass Screening IMS REP. Image: Rep- Image: Rep- <th>eview</th> <th>Investigate Report</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	eview	Investigate Report								
Injections View *Accurate Mass Screening IMS R.P. ** ** Synaptic2,2012.012,33 & * Synaptic2,2012.012,33 & * * * ** <td< th=""><th>4</th><th>Review Results 🔹</th><th></th><th></th><th></th><th></th><th></th><th>🖉 Limits 💌 🗟 Process</th><th>👔 Edit 🝷 🏟 Tools</th><th>🝷 🕞 🌌 File 👻</th></td<>	4	Review Results 🔹						🖉 Limits 💌 🗟 Process	👔 Edit 🝷 🏟 Tools	🝷 🕞 🌌 File 👻
Name Type SpraptG2_2012012,335 Component Summary Nork Barle Nork Component Summary Nork SpraptG2_2012012,335 SpraptG2_2012012,335 SpraptG2_2012012,335 SpraptG2_2012012,335 SpraptG2_2012012,335 SpraptG2_2012012,438 SpraptG2_2012002,438 SpraptG2_2012002,438 SpraptG2_2012002,438 SpraptG2_2012002,438 SpraptG2_2012002,438 SpraptG2_2012002,438 SpraptG2_20122001,037 SpraptG2_20122001,037 SpraptG2_20122001,037 SpraptG2_20122001,038 SpraptG2_201202002,038 SpraptG2_20120202,038 <th< td=""><td>jection</td><td>is and Components 👻 📲 📲</td><td>4</td><td>Tray: 1:6</td><td></td><td>SynaptG2_201229</td><td>. [1] • • Ø Ciprof</td><td>loxacin 🔹 🕞</td><td></td><td>Tilters</td></th<>	jection	is and Components 👻 📲 📲	4	Tray: 1:6		SynaptG2_201229	. [1] • • Ø Ciprof	loxacin 🔹 🕞		Tilters
SynaptG2_2012002,35 Mass Component m * m/z Observed collision cross section (Å) Expected collision cross section (Å) Mass error (ppm) Expected X (mn) SynaptG2_20120102,336 * 1 Corponent m * 332.1402 119.10 0.08 119.00 -0.79 2.22 SynaptG2_20120102,436 * 3 Danofoxacin 332.1402 108.72 0.02 108.70 -0.79 2.22 SynaptG2_2012202,438 * * Danofoxacin 358.155 114.66 -0.02 114.70 -1.66 2.34 SynaptG2_20122001,037 * * Danofoxacin,1 358.155 115.01 -0.01 115.00 -1.66 2.34 SynaptG2_2012201,038 * Danofoxacin,1 358.155 115.01 -0.01 135.06 -0.05 2.62 SynaptG2_2012201,038 * Diffoxacin,1 400.1467 135.06 0.00 135.06 -0.05 2.62 SynaptG2_2012201,038 * Diffoxacin,1 321.1358 118.17 0.00	Inje		Cor	mponent Summary	•			View: *Accurate Mass Scre	ening IMS REP 💌	; * # 🖲 🕻
SynaptG2_20120102_336 Image 11800 0.09 222 SynaptG2_20120102_436 2 Ciprofloxacin_1 332.1402 108.72 0.02 108.70 -0.79 222 SynaptG2_2012010_438 SynaptG2_2012010_438 3 Danofloxacin_1 358.1555 1124.68 -002 124.70 -1.68 2.34 SynaptG2_20122901_037 SynaptG2_20122901_038 4 Danofloxacin_1 358.1555 115.01 0.01 115.00 -1.68 2.34 SynaptG2_20122901_038 5 Difloxacin_1 400.1467 1135.06 0.00 1135.06 -0.05 2.62 SynaptG2_20122901_038 B Enofloxacin_1 321.1358 118.17 0.00 118.17 0.04 2.62 SynaptG2_20122901_038 B Enofloxacin_1 321.1358 118.17 0.00 118.17 0.04 2.62 SynaptG2_201290_01_038 Enofloxacin_1 321.1358 118.17 0.00 <t< td=""><td>-</td><td></td><td></td><td>Component n 1-</td><td>ı m/z</td><td>Observed collision cross section (Ų)</td><td>Collision cross section error (%)</td><td>Expected collision cross section (Å²)</td><td>Mass error (ppm)</td><td>Expected RT (min) O</td></t<>	-			Component n 1-	ı m/z	Observed collision cross section (Ų)	Collision cross section error (%)	Expected collision cross section (Å ²)	Mass error (ppm)	Expected RT (min) O
SynaptG2_2012001_436 * 332.4402 108.72 0.02 108.70 -0.79 2222 SynaptG2_2012001_438 * 3 Danofroxacin 358.1555 124.68 -0.02 124.70 -1.68 2.34 SynaptG2_20122901_037 * SynaptG2_20122901_038 * - <t< td=""><td>100</td><td>and the second second</td><td>1</td><td>Ciprofloxacin</td><td>332.1402</td><td>119.10</td><td>0.08</td><td>119.00</td><td>-0.79</td><td>2.22</td></t<>	100	and the second	1	Ciprofloxacin	332.1402	119.10	0.08	119.00	-0.79	2.22
SynaptG2_201220102438 Image: SynaptG2_20122901_037 Image: SynaptG2_20122901_037 Image: SynaptG2_20122901_038 Image: SynaptG2_2012901_038 Image: SynaptG2_201290_038 Image: SynaptG2_201290_038 Image: SynaptG2_201290_038 Image: SynaptG2_20129_038	1.00		2	Ciprofloxacin_1	332.1402	108.72	0.02	108.70	-0.79	2.22
SynaptG2_2012391_037 * Landroxach_1 398.1353 115.01 001 115.06 -1.68 2.24 SynaptG2_2012391_038 * 5 Difloxach_1 400.1467 135.06 0.00 135.06 -0.04 2.62 SynaptG2_2012391_038 * 1 400.1467 123.94 0.00 123.94 -0.04 2.62 SynaptG2_2012391_038 * 1 400.1467 123.94 0.00 123.94 -0.04 2.62 SynaptG2_2012391_038 * 1 13.06 10.00 123.94 -0.04 2.62 SynaptG2_2012391_038 * 1 321.1358 118.17 0.00 121.87 0.31 2.08 Components (SynaptG2_202 * 5 Endroxacin_1 360.1717 125.91 0.00 125.91 -0.27 2.40 10 Endroxacin_1 360.1717 125.91 0.00 121.87 2.22 2.31 11 Lomefoxacin_1 352.1475 111.83 0.03 111.50 2.22 2.31 12 Lomefoxacin_1 352.1475 <td></td> <td></td> <td>3</td> <td>Danofloxacin</td> <td>358.1555</td> <td>124.68</td> <td>-0.02</td> <td>124.70</td> <td>-1.68</td> <td>2.34</td>			3	Danofloxacin	358.1555	124.68	-0.02	124.70	-1.68	2.34
SynaptG2_2012290_038 SynaptG2_2012290_038 SynaptG2_2012290_039 SynaptG2_2012290_039 SynaptG2_2012290_039 SynaptG2_2012390_039 SynaptG2_			4	Danofloxacin_1	358.1555	115.01	0.01	115.00	-1.68	2.34
Symphology 2012/901/099 Image: Symphology 2013/901 Im	Syr		5	Difloxacin	400.1467	135.06	0.00	135.06	-0.05	2.62
Components (Synaptics) * Endfoxacin 321.1358 118.17 0.00 118.17 0.31 2.08 8 Endfoxacin 321.1359 104.68 0.00 104.68 0.33 2.08 9 Endfoxacin 360.1717 125.91 0.00 125.91 -0.27 2.40 10 Endfoxacin 360.1717 117.52 0.00 117.52 -0.29 2.40 11 Lomefoxacin 352.1475 121.87 0.00 121.87 2.22 2.31 12 Lomefoxacin 352.1475 111.53 0.03 111.50 2.22 2.31 13 Marbofoxacin 363.1466 113.05 0.00 113.05 0.77 2.04 14 Marbofoxacin 363.1466 113.05 0.00 118.04 1.39 2.15 15 Norfloxacin 363.1466 113.05 0.00 118.04 1.39 2.15 16 Norfloxacin 363.1466 113.05 0.00	Syr	naptG2_20122901_038 🔶	6	Difloxacin_1	400.1467	123.94	0.00	123.94	-0.04	2.62
Components (Synaptic2) Conditionation 1 S211339 Lokes Lokes <thlokes< th=""> <thlokes< th=""> <thlokes< th=""></thlokes<></thlokes<></thlokes<>	Syr	naptG2_20122901_039	7	Enofloxacin	321.1358	118.17	0.00	118.17	0.31	2.08
Sintus Name 1 5000 125.91 -0.27 2.40 Status Name 1 5000 117.52 0.00 117.52 -0.29 2.40 Status Name 1 5000 117.52 0.00 117.52 -0.29 2.40 Status Name 1 50000 117.52 0.00 117.52 -0.29 2.40 Status Caprofloxacin 3521475 121.87 0.00 121.87 2.22 2.31 O Danofloxacin 3531466 121.87 0.00 121.87 0.76 2.04 Marbofloxacin 3631466 121.87 0.00 113.05 0.77 2.04 Difloxacin 3631466 113.05 0.00 118.04 -1.39 2.15 O Difloxacin 363140 131.04 0.00 138.04 -1.39 2.15 O Difloxacin 366.1310 131.59 0.00 135.59 -0.24 2.58 <td>_</td> <td> }</td> <td>8</td> <td>Enofloxacin_1</td> <td>321.1359</td> <td>104.68</td> <td>0.00</td> <td>104.68</td> <td>0.33</td> <td>2.08</td>	_	}	8	Enofloxacin_1	321.1359	104.68	0.00	104.68	0.33	2.08
Status Name 1 Genofoxacin_1 360.1717 117.52 0.00 117.52 -0.29 2.40 Status Name 1 Lonefloxacin_1 352.1475 121.87 0.00 121.87 2.22 2.31 O Denofloxacin_1 352.1475 111.53 0.03 111.50 2.22 2.31 O Danofloxacin_1 352.1475 111.53 0.03 111.50 2.22 2.31 O Danofloxacin_1 352.1475 111.83 0.03 111.50 2.22 2.31 O Danofloxacin_1 363.1466 121.87 0.00 121.87 0.76 2.04 I Marbofloxacin_1 363.1466 113.05 0.00 113.05 0.77 2.04 Difloxacin_1 302.1401 118.04 0.00 118.04 -1.39 2.15 O Difloxacin_1 366.1310 131.59 0.00 135.59 -0.24 2.58 O Enofloxacin_1 366.1310 <td>-</td> <td></td> <td>9</td> <td></td> <td>360.1717</td> <td>125.91</td> <td>0.00</td> <td>125.91</td> <td>-0.27</td> <td>2.40</td>	-		9		360.1717	125.91	0.00	125.91	-0.27	2.40
Image: Ciprofloxacin Image: Ci	COL		10	Enrofloxacin_1	360.1717	117.52	0.00	117.52	-0.29	2.40
C profloxacin 12 Lomefloxacin_1 352.1475 111.53 0.03 111.50 2.22 2.31 Ø Danofloxacin 363.1466 121.87 0.00 121.87 0.76 2.04 Ø Danofloxacin 363.1466 113.05 0.00 113.05 0.77 2.04 Ø Danofloxacin_1 363.1466 113.05 0.00 118.04 .139 2.15 Ø Difloxacin 320.1401 118.04 0.00 118.04 .139 2.15 Ø Difloxacin_1 320.1401 106.26 0.00 106.26 .141 2.15 Ø Difloxacin_1 320.1400 106.26 0.00 106.26 .141 2.15 Ø Endfloxacin_1 386.1310 131.59 0.00 131.59 0.24 2.58 Ø Endfloxacin 1 386.1310 119.39 0.00 119.39 0.24 2.58	Sta	tus Name 1 🛋 📥	11	Lomefloxacin	352.1475	121.87	0.00	121.87	2.22	2.31
Ø Danoftoxacin 13 Marboftoxacin 363,1466 121,87 0.00 121,87 0.76 2.04 Ø Danoftoxacin,1 14 Marboftoxacin,1 363,1466 113,05 0.00 113,05 0.77 2.04 Ø Danoftoxacin,1 15 Norftoxacin,1 363,1466 113,05 0.00 118,04 -1.39 2.15 Ø Diftoxacin 15 Norftoxacin,1 320,1401 106,26 0.00 106,26 -1.41 2.15 Ø Diftoxacin,1 320,1400 106,26 0.00 135,59 -0.24 2.58 Ø Endfoxacin 386,1310 119,39 0.00 131,59 -0.24 2.58		Ciprofloxacin	12	Lomefloxacin_1	352.1475	111.53	0.03	111.50	2.22	2.31
O Danoffoxacin 14 Marboffoxacin_1 363.1466 113.05 0.00 113.05 0.77 2.04 Ø Defloxacin 15 Norfloxacin 320.1401 118.04 0.00 118.04 .139 2.15 Ø Difloxacin 16 Norfloxacin,1 320.1400 106.26 0.00 106.26 .141 2.15 Ø Difloxacin,1 320.1400 106.26 0.00 106.26 .141 2.15 Infloxacin 386.1310 131.59 0.00 131.59 -0.24 2.58 Infloxacin 18 Sarafioxacin 1 386.1310 119.39 0.00 119.39 -0.24 2.58		Ciprofloxacin_1	13	Marbofloxacin	363.1466	121.87	0.00	121.87	0.76	2.04
Operationacin_1 15 Norfloxacin 320,1401 118,04 0,00 118,04 1.39 2,15 O Difloxacin 16 Norfloxacin,1 320,1400 106,26 0,00 106,26 1,41 2,15 O Difloxacin,1 320,1400 106,26 0,00 106,26 1,41 2,15 In Sarafloxacin 386,1310 131,59 0,00 131,59 0,24 2,58 18 Sarafloxacin 1 386,1310 119,39 0,00 119,39 0,24 2,58	1	Danofloxacin	14		363,1466	113.05	0.00			2.04
Optioxacin 16 Norfloxacin,1 320,1400 106,26 0.00 106,26 1.41 2.15 Ø Difloxacin,1 17 Sarafloxacin 386,1310 131,59 0.00 131,59 -0.24 2,58 IB Sarafloxacin 1 386,1310 119,39 0.00 119,39 -0.24 2,58	1	Danofloxacin_1	15	MARKANO POIN						
O Diffoxacin_1 17 Sarafioxacin 386,1310 131.59 0.00 131.59 0.24 2.58 Image: Sarafioxacin 18 Sarafioxacin 1 386,1310 119.39 0.00 119.39 0.24 2.58	1	Difloxacin								
O Enoficiacin 18 Sarafioxacin 1 386.1310 119.39 0.00 119.39 -0.24 2.58	1	Difloxacin_1								
	1	D Enofloxacin								
	(Enofloxacin_1		- SerdiroxdCiri 1	500.1510	119.39	0.00		-0.24	2.50

Figure 4. Component Plot Summary showing nine identified fluoroquinolone antibiotics and nine pairs of CCS values.

These protomer gas phase components, although they only differ with the site of protonation, have different collision cross sections. The example of ciprofloxacin is shown in Figure 5, and in this case a difference of >10 Å² (angstrom is a unit of length equal to 10–10 m, one ten-billionth of a meter), was observed in this ion mobility study.¹¹ For all fluoroquinolone protomers pairs observed, the respective difference between CCS pair values varied between 6 Å² and 12 Å² with respect to the protomer pairs. The mobility separation achieved enabled individual precursor ion and fragments of all nine fluoroquinolones to be obtained in one analysis. From a single component fragmentation spectra it was possible to determine that for ciprofloxacin, the two mobility separated species resulted from protonation taking place either on the acidic or the basic group. From method development with standards, specific CCS information was generated providing further specific information to be entered into the UNIFI scientific library. Using this information, veterinary drug residues can now be identified based on retention time, accurate mass, fragments, and CCS values. Ciprofloxacin's estimated CCS values of 108.7 Å² and 119.1 Å² have been determined. Ciprofloxacin fragments at *m/z* 314 and *m/z* 231 are shown in Figure 6. These fragments are hypothesized to form from a species where ionization has taken place on the acidic group. Fragments observed at *m/z* 288 and *m/z* 245 resulted from protonation of the basic group.




Figure 5. Mobility trace for protomers of ciprofloxacin with hypothesised respective sites of acid/basic group protonation highlighted and determined estimated CCS values.




Figure 6. Ciprofloxacin acid and basic group single component fragmentation spectra generated using a UPLC ion mobility screening workflow in UNIFI.

Once the CCS values and fragments of the individual fluoroquinolones were entered into the UNIFI scientific library, a series of spiked porcine extracts were screened to determine the presence of fluoroquinolones. Examples of the screening results are shown in Figures 7 and 8, where the identification of two protomers of danofloxacin in porcine extract are presented. Here, the benefits of ion mobility resolution and the functionality of UNIFI are demonstrated, showing the resolved protomers, as well as the removal of the matrix background from the identified component danofloxacin. It can also be seen that for both protomers, mass accuracy <1 ppm was obtained, and that the CCS error was within 2% of the expected CCS values (124.7 Å² and 115.0 Å²). The observed retention time was 2.36 min and the individual protomer precursor

ion/fragmentation spectra have been obtained. This data further illustrates how confidence in true identifications can be increased when using UPLC ion mobility in conjunction with the functionality available within UNIFI Software.




Figure 7. Identification of two danofloxacin protomers identified in porcine extract, where no ion mobility resolution spectral cleanup has been selected. Precursor ion and fragmentation with matrix background ions are shown for danofloxacin protomer, expected CCS 124.7 Å².




Figure 8. Identification of two danofloxacin protomers identified in porcine extract, where ion mobility resolution spectral clean up has been selected. Precursor and fragmentation ions with matrix background ions removed, are shown for the danofloxacin protomer with expected CCS 124.70 Å².

The impact of the matrix upon the gas phase intra-molecular protonation for ciprofloxacin is shown in Figure 9. The ability to routinely process ion mobility data within a workflow has made it possible to clearly observe fluctuations in the ratios of the fluoroquinolone protomers formed. As discussed, each protomer generates specific fragments, and from this data, an understanding can be obtained of why fluctuations in observed ion ratios can occur when monitoring MRM transitions.




Figure 9. Consecutive acquisitions of replicate porcine extracts showing the impact of matrix upon the gas phase intra-molecular protonation for ciprofloxacin.

Multiple protonated species have been observed for the fluoroquinolone antibiotics screened. The extent of the protonation multiplicity and its experimental variation is still being investigated. This data confirms that further consideration should be given to method development and the means of analysis chosen, since the ratio and formation of the protomers can vary with the eluent flow rate, capillary voltage, cone voltage, and matrix.

If MRM is the method of choice, consideration of the experimental conditions used and the specific transitions selected is imperative. The data presented illustrate that consistency in MRM transitions in inter/intra laboratory studies could easily be misinterpreted within and between different laboratories, and demonstrates the challenges of achieving reproducible results for these types of compounds. Ion mobility can provide a valuable tool for method development in order to ensure method robustness and consistency of results.

The benefits of UPLC ion mobility mass spectrometry can be demonstrated over traditional 'shape selective' ion mobility-based separation techniques, such as Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS). FAIMS is typically used to transmit only ions of a particular mobility, essentially acting as a filter. Using the ACQUITY UPLC I-Class System with HDMS, the fastest, ion mobility separation can be performed for all components regardless of the sample complexity, maximizing the duty cycle of the analysis and the amount of information obtained. Having a compatible duty cycle available also ensures spectral integrity is retained.

The benefits of time-of-flight mass spectrometry and historical data review (retrospective data analysis) is well known. Such historical data review is also required with ion mobility mass spectrometry. The discovery

and presentation of multiple sites of protonation occurring during analysis for fluoroquinolone antibiotics can only be possible if the ion mobility data is acquired for all of the components in a sample. Continued development of the UNIFI platform's functionality has enabled routine screening using ion mobility mass spectrometry, facilitating the opportunity to develop more reproducible, repeatable, and robust assays for a wide range application areas.

Conclusion

- · Separation of different intra-molecular protonated species has been achieved uniquely using ion mobility.
- Single component precursor ion and fragmentation spectra can be generated for all components simultaneously.
- Multiple sites of protonation have been identified and confirmed from the individual fragmentation spectra of each protomer species.
- CCS values can be used as an identification point in addition to retention time, precursor ion accurate mass, and accurate mass fragmentation spectra.
- Ion mobility separations can be effectively utilized to resolve analyte peaks from matrix interferences and remove the need for complex sample cleanup.
- UPLC-ion mobility mass spectrometry observations have the potential to explain the differences sometimes observed in inter-laboratory studies, where participants report results obtained from monitoring specific MRM transitions.
- The UNIFI Scientific Information System enabled the routine interrogation of UPLC ion mobility MS data acquired using the SYNAPT G2-S and SYNAPT G2-Si HDMS systems.
- Based on the observations of characteristic ionization for fluoroquinolone antibiotics included in this study, the use of UPLC ion mobility for method development purposes is warranted.

References

1. M McCullagh, S Stead, J Williams, W de Keizer, A Bergwerff. Identification of Multiple Sites of Intra-

Molecular Protonation and Different Fragmentation Patterns within the Fluoroquinolone Class of Antibiotics in Porcine Muscle Extracts Using Travelling Wave Ion Mobility Mass Spectrometry. Waters Applicaton Note No. 720004720EN; June, 2013.

- E Verdon, P Couedor, B Roudaut, PJ Sandérs. Multiresidue method for simultaneous determination of ten quinolone antibacterial residues in multimatrix/multispecies animal tissues by liquid chromatography with fluorescence detection: single laboratory validation study. AOAC Inter. 2005; 88:1179–1192.
- A Kaufmann, P Butcher, K Maden, M Widmer, K Giles, D Uria. Are liquid chromatography/electrospray tandem quadrupole fragmentation ratios unequivocal confirmation criteria? *Rapid Commun. Mass Spectrom.* 2009; 23:985–998.
- 4. H G Mol, P Zomer, M de Koning. Qualitative aspects and validation of a screening method for pesticides in vegetables and fruits based on liquid chromatography coupled to full scan high resolution (Orbitrap) mass spectrometry. *Anal Bioanal Chem*. 2012; 403:2891–2908.
- 5. T R Croley, K D White, J H Callahan, S M Musser. The chromatographic role in high resolution mass spectrometry for non-targeted analysis. *J Am Soc Mass Spectrom*. 2012; 23:1569.
- 6. Commission Decision (2002/657EEC) Official Journal of the European Communities. 2002.
- Final Decision of the Commissioner, Docket # 2000N–I 57 1 October 24, 2000. Withdrawal of the approval of the new animal drug application for enrofloxacin in poultry. Department of Health and Human Services, U.S. Food and Drug Administration.
- 8. FDA Center for Veterinary Medicine, June 2, 1997, FDA order prohibits extra label use of fluoroquinolones and glycopeptides.
- 9. Official Journal of the European Union, L268:29–43, Regulation (EC) No 1831/2003 of the European parliament and of the council of 22 September 2003 on additives for use in animal nutrition.
- Official Journal of the European Union, L24:1–8 Annex I, Council Regulation (EEC) No 2377/90 of 26 June
 1990 laying down a community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.
- PM Lalli, BA Iglesias, HE Toma, GF de Sá, RJ Daroda, JC Silva Filho, JE Szulejko, K Araki, MN Eberlin. Protomers: formation, separation, and characterization via travelling wave ion mobility mass spectrometry. J Mass Spectrom. 2012; 47(6):712–9.

Acknowledgements

Waters kindly acknowledges Aldert Bergwerff and Wouter de Keizer (RnAssays) for the provision of the samples analyzed.

Featured Products

ACQUITY UPLC I-Class PLUS System <https://www.waters.com/134613317> SYNAPT G2-Si High Definition Mass Spectrometry <https://www.waters.com/134740622> MassLynx MS Software <https://www.waters.com/513662> UNIFI Scientific Information System <https://www.waters.com/134801359>

720005078, September 2017

©2019 Waters Corporation. All Rights Reserved.